AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. The new results come from the EMERALD-3 study, testing a ...
Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab ...
7d
A machine learning model may enable liver cancer risk prediction with routine clinical information
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results ...
"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...
Orphan Drug Designation is a key incentive established by the EMA to facilitate the development and authorisation of ...
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...
Using routine clinical data, the model gauges liver cancer risk better than existing tools, offering a potential way to identify high-risk patients missed by current screening criteria.
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma ...
Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results